|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM354233726 |
| 003 |
DE-627 |
| 005 |
20231226061756.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202300548
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1180.xml
|
| 035 |
|
|
|a (DE-627)NLM354233726
|
| 035 |
|
|
|a (NLM)36917817
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Li, Xiaoling
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Impairing Tumor Metabolic Plasticity via a Stable Metal-Phenolic-Based Polymeric Nanomedicine to Suppress Colorectal Cancer
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.06.2023
|
| 500 |
|
|
|a Date Revised 09.06.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Targeting metabolic vulnerability of tumor cells is a promising anticancer strategy. However, the therapeutic efficacy of existing metabolism-regulating agents is often compromised due to tolerance resulting from tumor metabolic plasticity, as well as their poor bioavailability and tumor-targetability. Inspired by the inhibitive effect of N-ethylmaleimide on the mitochondrial function, a dendronized-polymer-functionalized metal-phenolic nanomedicine (pOEG-b-D-SHNP) encapsulating maleimide-modified doxorubicin (Mal-DOX) is developed to enable improvement in the overall delivery efficiency and inhibition of the tumor metabolism via multiple pathways. It is observed that Mal-DOX and its derived nanomedicine induces energy depletion of CT26 colorectal cancer cells more efficiently than doxorubicin, and shifts the balance of programmed cell death from apoptosis toward necroptosis. Notably, pOEG-b-D-SH@NP simultaneously inhibits cellular oxidative phosphorylation and glycolysis, thus potently suppressing cancer growth and peritoneal intestinal metastasis in mouse models. Overall, the study provides a promising dendronized-polymer-derived nanoplatform for the treatment of cancers through impairing metabolic plasticity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a dendronized polymer
|
| 650 |
|
4 |
|a glycolysis
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
4 |
|a oxidative phosphorylation
|
| 650 |
|
4 |
|a tumor metabolic plasticity
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 700 |
1 |
|
|a Duan, Zhenyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Dayi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Qiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Lei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Gang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yinggang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Hu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gong, Qiyong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Rongjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Zhongwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Kui
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 23 vom: 05. Juni, Seite e2300548
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:23
|g day:05
|g month:06
|g pages:e2300548
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202300548
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 23
|b 05
|c 06
|h e2300548
|